CLINICAL TRIALS SECTION EDITOR: ANNE S. LINDBLAD, PhD Ranibizumab for Edema of the Macula in Diabetes Study 3-Year Outcomes and the Need for Prolonged Frequent Treatment Diana V. Do, MD; Quan D. Nguyen, MD, MSc; Afsheen A. Khwaja, MD; Roomasa Channa, MD; Yasir J. Sepah, MBBS; Raafay Sophie, MD; Gulnar Hafiz, MD, MPH; Peter A. Campochiaro, MD; for the READ-2 Study Group Objective: To assess the benefit of increased follow-up number of ranibizumab injections was significantly greater and treatment with ranibizumab between months 24 and in the ranibizumab group compared with the laser group 36 in the Ranibizumab for Edema of the Macula in Dia- (5.4 vs 2.3 injections, P = .008) but not compared with betes (READ-2) Study. the ranibizumab laser group (3.3, P = .11). Design: Prospective, interventional, multicenter fol- Conclusions: More aggressive treatment with rani- low-up of a randomized clinical trial. bizumab during year 3 resulted in a reduction in mean FTH and improvement in BCVA in the ranibizumab Methods: Patients who agreed to participate between group. More extensive focal/grid laser therapy in the other months 24 and 36 (ranibizumab, 28 patients; laser, 22; 2 groups may have reduced the need for more frequent and ranibizumab
JAMA Ophthalmology – American Medical Association
Published: Feb 1, 2013
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera